Reading the entry's description, Wu Ting felt a surge of excitement. 'Fengmu Tiada could actually generate such astronomical revenue!'
But on second thought, it made sense. After all, it was a curative drug for liver cancer, and the market was enormous. Otherwise, neither Jin Pharmaceutical Group nor Pfizer Pharmaceutical would value it so highly, willing to invest tens of billions into it.
During this time, Wu Ting had also learned some basic knowledge about pharmaceutical companies and new drug development:
The profits from a top-tier new drug were insane and staggering!
For example, one drug had raked in 14.2 billion dollars in just nine months, causing the Danish biopharmaceutical company Novo Nordisk's market cap to soar to 460 billion dollars. It became the top listed company in the Southern Continent, with a valuation that dwarfed Denmark's entire annual GDP.
